EQUILLIUM, INC. (EQ) Current Ratio
- Current ratio · latest quarter: Value 23.40×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 23.40× | Current assets / current liabilities. $57.98M ÷ $2.48M ≈ 23.40× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 57.98M USD | Assets, Current |
| Current obligations | 2.48M USD | Liabilities, Current |
| Cash and equivalents | 57.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 850.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $57.98M | $2.48M | $57.16M | (m) | (m) | (m) | $850.00K | (m) | 23.40× |
| 2026-03-31 | $62.27M | $3.35M | $61.32M | (m) | (m) | (m) | $1.29M | (m) | 18.62× |
| 2025-12-31 | $31.04M | $2.93M | $30.28M | (m) | (m) | (m) | $755.00K | (m) | 10.58× |
| 2025-09-30 | $33.58M | $3.09M | $33.12M | $0.00 | (m) | (m) | $1.08M | (m) | 10.85× |
| 2025-06-30 | $11.95M | $7.23M | $11.49M | $0.00 | (m) | (m) | $4.81M | (m) | 1.65× |
| 2025-03-31 | $16.22M | $6.00M | $14.50M | $0.00 | (m) | (m) | $3.06M | (m) | 2.70× |
| 2024-12-31 | $24.98M | $6.36M | $18.09M | $4.49M | (m) | (m) | $2.68M | (m) | 3.93× |
| 2024-09-30 | $33.65M | $11.06M | $15.45M | $10.43M | $5.01M | (m) | $3.67M | (m) | 3.04× |
| 2024-06-30 | $41.89M | $20.17M | $11.06M | $22.24M | $5.89M | (m) | $4.49M | (m) | 2.08× |
| 2024-03-31 | $42.48M | $22.21M | $11.57M | $20.72M | $5.05M | (m) | $2.78M | (m) | 1.91× |
| 2023-12-31 | $49.35M | $27.57M | $23.22M | $17.65M | $3.73M | (m) | $4.71M | (m) | 1.79× |
| 2023-09-30 | $53.91M | $28.20M | $34.38M | $11.92M | $3.77M | (m) | $3.63M | (m) | 1.91× |
| 2023-06-30 | $57.36M | $25.22M | $25.62M | $22.75M | $3.74M | (m) | $3.03M | (m) | 2.27× |
| 2023-03-31 | $70.22M | $32.02M | $24.50M | $37.49M | $3.42M | (m) | $5.69M | $5.71M | 2.19× |
| 2022-12-31 | $76.73M | $32.04M | $59.11M | $11.92M | $2.84M | (m) | $3.98M | (m) | 2.40× |
| 2022-09-30 | $46.78M | $14.93M | $25.73M | $18.79M | (m) | (m) | $2.47M | $5.71M | 3.13× |
| 2022-06-30 | $60.48M | $15.19M | $23.81M | $33.75M | (m) | (m) | $5.09M | $4.29M | 3.98× |
| 2022-03-31 | $72.08M | $13.11M | $26.24M | $42.58M | (m) | (m) | $4.21M | $2.86M | 5.50× |
| 2021-12-31 | $83.37M | $8.91M | $50.37M | $30.34M | $0.00 | (m) | $1.23M | (m) | 9.35× |
| 2021-09-30 | $92.17M | $7.78M | $77.16M | $13.54M | (m) | (m) | $2.67M | $1.25M | 11.85× |
| 2021-06-30 | $99.57M | $4.98M | $73.53M | $24.12M | (m) | (m) | $1.82M | $0.00 | 19.99× |
| 2021-03-31 | $106.61M | $7.42M | $50.86M | $53.22M | (m) | (m) | $2.32M | $2.50M | 14.37× |
| 2020-12-31 | $85.17M | $7.25M | $23.98M | $58.18M | (m) | (m) | $2.77M | (m) | 11.76× |
| 2020-09-30 | $92.16M | $5.14M | $49.25M | $41.29M | (m) | (m) | $1.68M | $833.00K | 17.91× |
| 2020-06-30 | $44.18M | $3.39M | $24.08M | $18.52M | (m) | (m) | $1.76M | (m) | 13.04× |
| 2020-03-31 | $49.82M | $3.71M | $20.61M | $27.06M | (m) | (m) | $1.80M | (m) | 13.43× |
| 2019-12-31 | $55.43M | $3.88M | $13.22M | $39.92M | (m) | (m) | $1.87M | (m) | 14.28× |
| 2019-09-30 | $62.91M | $4.27M | $27.66M | $34.58M | (m) | (m) | $2.67M | (m) | 14.72× |
| 2019-06-30 | $57.80M | $3.66M | $22.66M | $34.28M | (m) | (m) | $1.97M | (m) | 15.78× |
| 2019-03-31 | $62.63M | $3.05M | $21.39M | $40.21M | (m) | (m) | $1.59M | (m) | 20.52× |
| 2018-12-31 | $67.10M | $2.03M | $28.51M | $37.41M | (m) | (m) | $1.12M | (m) | 33.09× |
| 2018-09-30 | $5.06M | $2.68M | $4.98M | (m) | (m) | (m) | $1.23M | (m) | 1.89× |
| 2017-12-31 | $7.15M | $568.82K | $7.10M | $0.00 | (m) | (m) | $243.74K | (m) | 12.57× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |